| Major Pharmaceutical Preparations Industry |
2 Q |
1 Q |
4 Q |
3 Q |
2 Q |
|
|
Q2 2025 |
Q1 2025 |
FY 2024 and Q4 2024 |
Q3 2024 |
Q2 2024 |
| Y / Y Revenue Quarterly Growth |
264.34 % |
4.44 % |
11.85 % |
10.2 % |
5.18 % |
| Sequential Revenue Quarterly Growth |
138.75 % |
-7.73 % |
2.78 % |
3.89 % |
5.61 % |
| Revenue Growth Overall Ranking Y/Y |
# 1 |
# 39 |
# 19 |
# 19 |
# 38 |
| Y / Y Revenue Annual Growth (at the end of Fiscal Year) |
|
|
6.32 % |
|
|
| Y / Y Revenue Growth (12 Months at Quarter Ending) |
41.86 % |
8.03 % |
6.32 % |
2.79 % |
-1.46 % |
| Sequential Revenue Growth (12 Months at Quarter Ending) |
56.66 % |
0.79 % |
2.17 % |
2.55 % |
1.33 % |
| Revenue Growth Ranking Y/Y (TTM) |
# 1 |
# 34 |
# 37 |
# 53 |
# 62 |
| Y / Y Operating Income Quarterly Growth |
- |
161.29 % |
145.23 % |
84.01 % |
81.98 % |
| Sequential Operating Income Quarterly Growth |
- |
59.52 % |
-38.37 % |
41.26 % |
93.12 % |
| Operating Income Overall Ranking Y/Y |
# 1 |
# 39 |
# 19 |
# 19 |
# 36 |
| Y / Y Operating Income Annual Growth (at the end of Fiscal Year) |
- |
|
18.33 % |
|
|
| Y / Y Operating Income Growth (12 Months trailing by quarter ending) |
- |
143.69 % |
18.33 % |
-25.78 % |
-50.27 % |
| Sequential Operating Income Growth (12 Months trailing by quarter ending) |
- |
23.45 % |
13.85 % |
26.59 % |
23.81 % |
| Operating Income Growth Ranking Y/Y (TTM) |
# 1 |
# 34 |
# 37 |
# 55 |
# 62 |
| Y / Y Income from Cont. Ops Quarterly Growth |
- |
759.43 % |
97.14 % |
139.58 % |
167.77 % |
| Sequential Income from Cont. Ops Quarterly Growth |
- |
13.65 % |
14.68 % |
56.55 % |
406.8 % |
| Income from Cont. Ops Overall Ranking Y/Y |
# 1 |
# 39 |
# 19 |
# 19 |
# 36 |
| Y / Y Income from Cont. Ops Annual Growth (at the end of Fiscal Year) |
- |
|
21.73 % |
|
|
| Y / Y Income from Cont. Ops Growth (12 Months trailing by quarter ending) |
- |
216.69 % |
21.73 % |
15.9 % |
-40.94 % |
| Sequential Income from Cont. Ops Growth (12 Months trailing by quarter ending) |
- |
43.64 % |
6.25 % |
35.59 % |
33.69 % |
| Income from Cont. Ops Growth Ranking Y/Y (TTM) |
# 1 |
# 34 |
# 37 |
# 55 |
# 62 |
| Y / Y Net Income Quarterly Growth |
- |
752.28 % |
101.47 % |
-41.22 % |
168.59 % |
| Sequential Net Income Quarterly Growth |
- |
13.62 % |
16.75 % |
55.91 % |
411.39 % |
| Net Income Overall Ranking Y/Y |
# 1 |
# 39 |
# 19 |
# 19 |
# 36 |
| Y / Y Net Income Annual Growth (at the end of Fiscal Year) |
- |
|
-22.62 % |
|
|
| Y / Y Net Income Growth (12 Months trailing by quarter ending) |
- |
49.34 % |
-22.62 % |
-31.84 % |
-0.25 % |
| Sequential Net Income Growth (12 Months trailing by quarter ending) |
- |
43.57 % |
7.13 % |
-23.72 % |
16.85 % |
| Net Income Growth Ranking Y/Y (TTM) |
# 1 |
# 34 |
# 37 |
# 55 |
# 62 |
| Y / Y Free Cash Flow Quarterly Growth |
- |
-5.02 % |
32.14 % |
24.5 % |
-10.76 % |
| Sequential Free Cash Flow Quarterly Growth |
- |
-55.4 % |
-17.82 % |
190.31 % |
-10.11 % |
| Free Cash Flow Overall Ranking Y/Y |
# 1 |
# 39 |
# 19 |
# 19 |
# 36 |
| Y / Y Free Cash Flow Annual Growth (at the end of Fiscal Year) |
- |
|
12.81 % |
|
|
| Y / Y Free Cash Flow Growth (12 Months trailing by quarter ending) |
- |
11.65 % |
12.81 % |
0.91 % |
-3.48 % |
| Sequential Free Cash Flow Growth (12 Months trailing by quarter ending) |
- |
-0.53 % |
7.2 % |
8.1 % |
-2.05 % |
| Free Cash Flow Growth Ranking Y/Y (TTM) |
# 1 |
# 34 |
# 37 |
# 55 |
# 62 |
| Y / Y Capital Expenditures Quarterly Growth |
38.1 % |
19.87 % |
3.65 % |
2.19 % |
-2.06 % |
| Sequential Capital Expenditures Quarterly Growth |
-23.24 % |
-18.63 % |
26.42 % |
9.65 % |
5.24 % |
| Capital Expenditures Overall Ranking Y/Y |
# 1 |
# 39 |
# 19 |
# 19 |
# 36 |
| Y / Y Capital Expenditures Annual Growth (at the end of Fiscal Year) |
|
|
3.88 % |
|
|
| Y / Y Capital Expenditures Growth (12 Months trailing by quarter ending) |
7.57 % |
10.01 % |
3.88 % |
5.59 % |
2.94 % |
| Sequential Capital Expenditures Growth (12 Months trailing by quarter ending) |
7.47 % |
4.45 % |
1.04 % |
1.69 % |
1.65 % |
| Capital Expenditures Growth Ranking Y/Y (TTM) |
# 1 |
# 34 |
# 37 |
# 55 |
# 62 |
